It means the hormone has the same molecular structure as the corresponding hormone produced by the human body.

The terms overlap, but they are not identical. Menopausal hormone therapy describes the clinical use of hormones to treat menopause-related symptoms and, in selected cases, prevent bone loss. BHRT specifically refers to hormones that are structurally identical to human hormones.

We use personalised compounded bioidentical hormones when clinically appropriate because they allow the formulation, strength and delivery method to be tailored to an individual’s specific needs.

Compounding itself does not automatically make hormone therapy safer. Safety comes from appropriate patient selection, a reliable compounding pharmacy, accurate prescribing, the lowest suitable dose and regular clinical monitoring. Every plan is therefore based on the person’s symptoms, medical history, relevant investigations, response to treatment and evolving risk profile.

Not always. In women over 45 with a typical perimenopausal pattern, diagnosis is often based on symptoms and menstrual history because hormone levels can fluctuate from day to day. Testing becomes more useful when symptoms occur at a younger age, the diagnosis is unclear, periods are absent for another reason, testosterone or thyroid treatment is being considered, or another medical condition needs to be excluded.

Some people notice improvement in hot flushes, night sweats or sleep within a few weeks. Other symptoms may take several weeks to a few months. If there is no meaningful improvement after an adequate trial, the diagnosis, dose, delivery method and other contributing factors should be reassessed.

BHRT is not a weight-loss treatment. It may improve sleep, vasomotor symptoms and wellbeing, which can make healthy habits easier to sustain. Body-composition changes during midlife still require attention to protein intake, resistance exercise, sleep, metabolic health and overall energy balance.

Hormone therapy may improve these concerns when they are linked to hot flushes, night sweats, poor sleep or the menopause transition. Persistent or severe cognitive or mood symptoms need a broader assessment. BHRT is not a substitute for appropriate mental-health or neurological care.

If you have a uterus and use systemic synthetic estrogen, you will generally need adequate progesterone or another progestogen to protect the uterine lining. Estrogen alone may be appropriate after a total hysterectomy, depending on individual circumstances.

Progesterone-related hormones exist in both women and men. However, progesterone treatment is men depends on clinical symptoms.

Can women benefit from testosterone?

Absolutely—testosterone is an important female hormone too. Women produce it naturally through the ovaries and adrenal glands, and levels generally decline gradually from early adulthood. By the late 30s, during perimenopause and after menopause, some women become more aware of the combined hormonal changes.

They may experience :
Reduced sexual desire and arousal.
Lower energy, drive or motivation.
Difficulty maintaining muscle and strength.
Changes in body composition.
Reduced mental clarity.
Lower overall sense of vitality.
Testosterone also plays a physiological role in female sexual health, muscle, bone and overall wellbeing. However, these symptoms can also arise from changes in estrogen, thyroid function, sleep, stress, nutrition, medication or relationship factors.

Only confirmed testosterone deficiency should be treated. Symptoms alone are not enough; diagnosis generally requires compatible symptoms plus consistently low morning testosterone levels on repeat testing and an evaluation for the cause. Testosterone treatment can affect fertility, red-blood-cell count, prostate monitoring and cardiovascular risk assessment.

DHEA is an adrenal precursor hormone that can be converted into androgens and estrogens. It is not a routine “anti-ageing” supplement. Low DHEA-S accompanied by severe fatigue, unexplained weight loss, low blood pressure, dizziness, nausea, salt cravings, low sodium or skin darkening needs evaluation for adrenal insufficiency.

Risk depends on the individual, the hormones used and duration of treatment. Combined systemic estrogen-progestogen therapy and estrogen-only therapy do not have identical risk profiles. Personal breast history, family history, screening and treatment duration must be considered.

Light irregular bleeding can occur during the first months of some regimens, particularly in perimenopause. However, heavy, persistent, recurrent or new bleeding after a period of no bleeding requires medical evaluation. Any postmenopausal bleeding should be discussed promptly.

There is no single stop date that applies to everyone. Treatment should continue only while the expected benefits outweigh the risks, with periodic review. Age alone does not automatically determine whether therapy must stop, but starting systemic therapy later in life can carry a different risk profile.

Symptoms may or may not return. Some people taper treatment while others stop directly, depending on the regimen and medical advice.For e.g Bone-protection benefits reduce after systemic hormone therapy is stopped, so an alternative bone-health plan may be needed when fracture risk is significant.

Monitoring is personalised and may include symptom review, blood pressure, weight or body composition when relevant, breast and cervical screening according to age and local guidelines, assessment of unexpected bleeding and selected laboratory tests. Testosterone therapy requires additional monitoring to avoid excessive levels. More testing is not always better; the right testing is what matters.

Yes, when both are clinically indicated, but they are separate treatments.

Yes. Depending on the symptom, options may include lifestyle support, vaginal moisturisers and lubricants, pelvic-floor care, cognitive behavioural therapy and prescription non-hormonal medicines for hot flushes or other symptoms. A person who cannot or does not wish to use hormones still deserves an active treatment plan.

The information on this page is for general education and does not replace individual medical advice, diagnosis or treatment. Hormone therapy is prescription treatment and may not be suitable for everyone. Benefits, risks, contraindications and monitoring requirements must be reviewed with a qualified medical professional. Seek urgent medical care for severe or sudden symptoms.

Suggested SEO title :
Bioidentical Hormone Replacement Therapy (BHRT) in Mumbai | Kiiran Patel Wellness Cube.

Suggested meta description :
Explore personalised BHRT at Kiiran Patel Wellness Cube, Mumbai. Learn about estrogen, progesterone, testosterone and DHEA, potential benefits, safety, testing and monitoring.

No. These foundations remain central to metabolism, muscle, recovery and long-term health. Treatment should support—not replace—the behaviours that maintain results.

Contact the prescribing clinical team. Depending on the medicine and severity, the plan may require slower titration, dose adjustment may be required.

---

Suggested website disclaimer : The information on this page is for general education and does not constitute medical advice or promotion of an unapproved product. Peptide-based medicines are prescription treatments whose approval and lawful availability vary by country and indication. Several compounds discussed online remain investigational, with limited human safety and effectiveness data. Treatment decisions must be made with an appropriately qualified medical professional following individual assessment and informed consent.

Suggested SEO title : Peptide Therapy Consultation in Mumbai | Kiiran Patel Wellness Cube.

Suggested meta description : Explore peptide-based therapies with Kiiran Patel Wellness Cube, Mumbai. Understand approved versus investigational peptides, personalised assessment, safety and monitoring.